Artivion (AORT) Amends Agreements with Endospan

Go back to Artivion (AORT) Amends Agreements with Endospan

Artivion Amends Agreements with Endospan

July 1, 2024 4:05 PM EDT

Provides Endospan with $25 million of Additional Debt Funding to Obtain FDA Approval for NEXUS

Upfront Payment Associated with Purchase Option Reduced to $135 million, inclusive of loan off-set, and $100 million earnout minimum eliminated 

ATLANTA, July 1, 2024 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic... More